[HTML][HTML] Oral lipid nanocomplex of BRD4 PROteolysis TArgeting chimera and vemurafenib for drug-resistant malignant melanoma
BRAF inhibitors (BRAFi) like vemurafenib (VEM) provide initial regression in mutated
melanoma but rapidly develop resistance. Molecular pathways responsible for development …
melanoma but rapidly develop resistance. Molecular pathways responsible for development …
Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma
A Saraswat, R Vartak, R Hegazy, Y Fu… - Biomedicine & … - pubmed.ncbi.nlm.nih.gov
BRAF inhibitors (BRAFi) like vemurafenib (VEM) provide initial regression in mutated
melanoma but rapidly develop resistance. Molecular pathways responsible for development …
melanoma but rapidly develop resistance. Molecular pathways responsible for development …
Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.
A Saraswat, R Vartak, R Hegazy, Y Fu… - Biomedicine & …, 2023 - europepmc.org
BRAF inhibitors (BRAFi) like vemurafenib (VEM) provide initial regression in mutated
melanoma but rapidly develop resistance. Molecular pathways responsible for development …
melanoma but rapidly develop resistance. Molecular pathways responsible for development …